Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 668

1.

Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.

Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, Anderson EL, Steinhoff MC, Edwards KM.

Pediatrics. 2000 Jan;105(1):e12.

PMID:
10617749
2.

Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.

Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD.

Pediatrics. 2000 Jan;105(1):e11.

PMID:
10617748
3.

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD.

Pediatrics. 1997 Nov;100(5):772-88.

PMID:
9346976
4.

Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

Tozzi AE, Anemona A, Stefanelli P, Salmaso S, Ciofi degli Atti ML, Mastrantonio P, Giammanco A; Progetto Pertosse Study Group.

Pediatrics. 2001 Feb;107(2):E25.

PMID:
11158499
5.

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group.

Pediatrics. 2001 Nov;108(5):E81.

PMID:
11694665
7.

Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.

Richie E, Punjabi NH, Harjanto SJ, Wangsasaputral F, Sukandar M, Supriatman M, Simanjuntak CH, Que JU, Cryz SJ Jr.

Vaccine. 1999 Mar 17;17(11-12):1384-93.

PMID:
10195774
8.

A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.

Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM.

Pediatr Infect Dis J. 2005 Dec;24(12):1059-66. Erratum in: Pediatr Infect Dis J. 2006 Mar;25(3):229.

PMID:
16371866
9.

Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.

Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C.

Scand J Infect Dis. 1996;28(2):159-63.

PMID:
8792483
10.

Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.

Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, Meekison W, Eastwood BJ.

Pediatr Infect Dis J. 1999 Sep;18(9):772-9.

PMID:
10493336
12.

Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group.

Liese JG, Stojanov S, Zink TH, Froeschle J, Klepadlo R, Kronwitter A, Harzer E, Jow S, Belohradsky BH.

Pediatr Infect Dis J. 2001 Oct;20(10):981-8.

PMID:
11642633
13.

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.

Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR.

J Pediatr. 2006 Nov;149(5):603-610.

PMID:
17095328
14.

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.

Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.

Vaccine. 2006 Jul 7;24(27-28):5627-36. Epub 2006 May 2.

PMID:
16740348
15.

Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.

Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.

Pediatr Infect Dis J. 2008 Apr;27(4):341-6. doi: 10.1097/INF.0b013e3181616180.

PMID:
18316985
16.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
19.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.

Bernstein HH, Rothstein EP, Reisinger KS, Blatter MM, Arbeter AM, Fontana ME, Jacobs JM, Long SS, Rathfon H, Crayne O, et al.

Pediatrics. 1994 Apr;93(4):656-9.

PMID:
8134224
20.
Items per page

Supplemental Content

Write to the Help Desk